Research Analysts Set Expectations for SNDX FY2025 Earnings

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) – Stock analysts at HC Wainwright upped their FY2025 earnings estimates for Syndax Pharmaceuticals in a research note issued on Tuesday, November 4th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings per share of ($3.04) for the year, up from their prior forecast of ($3.05). HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Syndax Pharmaceuticals’ current full-year earnings is ($3.72) per share. HC Wainwright also issued estimates for Syndax Pharmaceuticals’ Q4 2025 earnings at ($0.53) EPS, Q1 2026 earnings at ($0.42) EPS, Q2 2026 earnings at ($0.31) EPS, Q3 2026 earnings at ($0.21) EPS, Q4 2026 earnings at ($0.07) EPS, FY2026 earnings at ($1.01) EPS, FY2027 earnings at ($0.21) EPS, FY2028 earnings at $0.78 EPS and FY2029 earnings at $2.39 EPS.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its quarterly earnings results on Monday, November 3rd. The company reported ($0.70) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.04. The company had revenue of $45.87 million for the quarter, compared to analysts’ expectations of $49.08 million. Syndax Pharmaceuticals had a negative net margin of 428.48% and a negative return on equity of 130.47%. The business’s quarterly revenue was up 266.4% compared to the same quarter last year. During the same period last year, the firm posted ($0.98) earnings per share.

Several other research firms have also recently commented on SNDX. BTIG Research reaffirmed a “buy” rating and issued a $56.00 price objective on shares of Syndax Pharmaceuticals in a research report on Monday, October 27th. B. Riley raised shares of Syndax Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, August 6th. The Goldman Sachs Group lifted their price target on shares of Syndax Pharmaceuticals from $20.00 to $24.00 and gave the company a “buy” rating in a research note on Friday, September 5th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Syndax Pharmaceuticals in a research note on Wednesday, October 8th. Finally, Guggenheim assumed coverage on shares of Syndax Pharmaceuticals in a research note on Thursday, September 4th. They issued a “buy” rating and a $34.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Syndax Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $36.70.

Syndax Pharmaceuticals Trading Down 1.6%

SNDX opened at $15.10 on Thursday. The stock has a market capitalization of $1.30 billion, a P/E ratio of -3.88 and a beta of 0.73. Syndax Pharmaceuticals has a 12 month low of $8.58 and a 12 month high of $22.50. The firm’s fifty day simple moving average is $15.30 and its 200 day simple moving average is $12.63. The company has a current ratio of 4.71, a quick ratio of 4.55 and a debt-to-equity ratio of 2.06.

Insider Activity

In other news, CEO Michael A. Metzger sold 157,307 shares of the business’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $16.41, for a total transaction of $2,581,407.87. Following the transaction, the chief executive officer directly owned 298,661 shares in the company, valued at $4,901,027.01. The trade was a 34.50% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Dennis Podlesak sold 19,200 shares of the business’s stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $15.84, for a total transaction of $304,128.00. Following the transaction, the director owned 191,763 shares in the company, valued at $3,037,525.92. This represents a 9.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 195,707 shares of company stock worth $3,183,904 over the last 90 days. 4.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of SNDX. Bank of America Corp DE grew its stake in Syndax Pharmaceuticals by 33.7% in the 2nd quarter. Bank of America Corp DE now owns 3,838,872 shares of the company’s stock valued at $35,951,000 after buying an additional 967,873 shares during the last quarter. Qube Research & Technologies Ltd grew its stake in Syndax Pharmaceuticals by 99.5% in the 2nd quarter. Qube Research & Technologies Ltd now owns 1,665,916 shares of the company’s stock valued at $15,601,000 after buying an additional 831,067 shares during the last quarter. Adage Capital Partners GP L.L.C. grew its stake in Syndax Pharmaceuticals by 126.8% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 1,432,440 shares of the company’s stock valued at $13,415,000 after buying an additional 800,800 shares during the last quarter. Stempoint Capital LP grew its stake in Syndax Pharmaceuticals by 48.4% in the 2nd quarter. Stempoint Capital LP now owns 2,372,634 shares of the company’s stock valued at $22,220,000 after buying an additional 774,040 shares during the last quarter. Finally, Jump Financial LLC acquired a new position in Syndax Pharmaceuticals in the 2nd quarter valued at about $3,568,000.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).